AOA Dx
also invests · investor profileYC S21Denver, US · Founded 2020 · Delaware corporation · 25 employees · 25 known investors
AOA Dx develops a blood-based liquid biopsy platform using mass spectrometry and machine learning to detect ovarian cancer at early stages through tumor-associated biomarkers in serum. The company serves oncologists and patients in women's health diagnostics.
Also known as AOA Dx Inc.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesHealthcareDiagnosticsWomen's HealthUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S21)
AOA Dx was founded in 2020 by Oriana Papin-Zoghbi, Alex Fisher, Anna Jeter, and Oriana Zoghbi-Harb.
OP
Oriana Papin-Zoghbiin𝕏CEO & Co-FounderOriana Papin-Zoghbi is CEO and co-founder of AOA Dx Inc., a company focused on women's health diagnostics.
AF
Alex FisherinCo-FounderAlex Fisher is Chief Operating Officer and Co-Founder of AOA Dx, a women's health company.
AJ
Anna Jeterin𝕏Chief Regulatory Officer and Co-founderAnna Jeter is Chief Business Officer and co-founder of AOA Dx.
OZ
Oriana Zoghbi-HarbCo-founder
AM
Abigail McelhinnyExecutive
Board
SS
Surbhi SarnaBoard director
JF
Investors · 25
AlleyCorp✓ verifiedNew York · $1M – $5M
Good Growth Capital✓ verifiedCharleston
Joyance Partners✓ verifiedBerlin
Y Combinator✓ verifiedSan Francisco · $500K
AstiaSilicon Valley
Aurum Venture PartnersPleasanton
Bantam GroupWestwood
Beacon AngelsBoston · $50K – $400K
Cancer FundPhoenix
Creative Destruction Lab (CDL)Toronto · $50K – $250K
Emmeline VenturesParadise Valley · $50K – $500K
FemHealth VenturesShort Hills
Foreground CapitalBoston
Kube VC
Launchpad Venture GroupBoston · $8M – $10M
LongeVCWashington D.C.
Olive Tree CapitalBoston
Oxonian VenturesPalo Alto
TBD AngelsNew York
Undeterred CapitalLos Angeles · $500K – $1Mvia Joe Wilson · inferred
VU Venture PartnersSan Francisco · $200K – $1M
Walnut Venture AssociatesWellesley
Alley Robotics VenturesreportedCohasset · $500K – $2Mvia Abe Murray · inferred
Gore Range CapitalreportedSouthlake · $500K – $5M
HelmreportedNew York · $500K
Reported raises · per SEC filings
Form D private placements$38.7M disclosed across 5 rounds · 2021–2025
▶$8.1MraisedOct 2025 · 40 investors · BiotechnologyRule 506(b)
▶$8.1MraisedOct 2025 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Surbhi SarnaDirector
- Anna Milik JeterExecutive Officer
- Abigail McelhinnyExecutive Officer
- Oriana Papin-ZoghbiExecutive Officer, Director
- John FriedmanDirector
- Alexander James FisherExecutive Officer
- Offering amount
- $30.6M
- Amount sold
- $8.1M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedDec 2024 · 15 investors · BiotechnologyRule 506(b)
▶$1.8MraisedDec 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander James FisherExecutive Officer
- Surbhi SarnaDirector
- Anna Milik JeterExecutive Officer
- John FriedmanDirector
- Oriana Papin-ZoghbiExecutive Officer, Director
- Abigail McelhinnyExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $1.8M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$23.6MraisedJul 2023 · 119 investors · BiotechnologyRule 506(b)
▶$23.6MraisedJul 2023 · 119 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Surbhi SarnaDirector
- Anna Milik JeterExecutive Officer
- Oriana Papin-ZoghbiExecutive Officer, Director
- John FriedmanDirector
- Alexander James FisherExecutive Officer
- Offering amount
- $24.2M
- Amount sold
- $23.6M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.6MraisedNov 2021 · 33 investors · BiotechnologyRule 506(b)
▶$2.6MraisedNov 2021 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anna Milik JeterExecutive Officer, Director
- Surbhi SarnaDirector
- Alexander FisherExecutive Officer, Director
- Oriana Zoghbi-HarbExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.6M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.5MraisedJul 2021 · 38 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2021 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anna Milik JeterExecutive Officer, Director
- Alexander James FisherExecutive Officer, Director
- Oriana Zoghbi-HarbExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
The YC application· Summer 2021 batch
What they told YC
- How long have each of you been working on this? How much of that has been full-time? Please explain.
- The founders have worked on the project for two years. Following the exit of a prior startup, they evaluated more than 20 technologies from various countries before partnering with Prof. Uri Saragovi of McGill University, who developed a method for early ovarian cancer diagnosis. CEO Oriana has been full-time since September 2019, and the two other co-founders joined full-time in October 2020.
- What is your company going to make? Please describe your product and what it does or will do.
- The company is building a non-invasive blood-based liquid biopsy test to diagnose ovarian cancer at early stages. It addresses the fact that about 80% of cases are currently diagnosed at stages III and IV, where the five-year survival rate is 28%, compared with 90% for early-stage diagnosis, since existing methods lack sensitivity and specificity in stages I and II.
Summarized from the founders' answers on their Y Combinator profile.
Images
Competitors · 3
by search overlap
Affineon4 shared keywordsAffineon offers an AI-powered inbox tool that works within electronic health record systems to automatically handle lab results and prescription renewals for healthcare providers and their care teams. It also provides a white-label program (Affineon Embed) for EHR systems, AI scribes, and other healthcare technology companies to integrate its AI inbox into their products.
Labcorp4 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
CareDx4 shared keywordsCareDx provides molecular diagnostic testing, workflow software, patient support, and pharmacy services for care teams working in transplant, cell therapy, and specialty oncology. Its products support rejection monitoring and complex care management in precision medicine.
Companies competing with AOA Dx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does AOA Dx do?
- AOA Dx develops a blood-based liquid biopsy platform using mass spectrometry and machine learning to detect ovarian cancer at early stages through tumor-associated biomarkers in serum. The company serves oncologists and patients in women's health diagnostics.
- Who founded AOA Dx?
- AOA Dx was founded by Oriana Papin-Zoghbi, Alex Fisher, Anna Jeter, Oriana Zoghbi-Harb in 2020.
- Who are AOA Dx's investors?
- AOA Dx's investors include AlleyCorp, Good Growth Capital, Joyance Partners, Y Combinator, Astia, Aurum Venture Partners, Bantam Group, Beacon Angels and 17 more.
- How much funding has AOA Dx raised?
- AOA Dx has disclosed $38.7M raised across 5 rounds.
- Where is AOA Dx headquartered?
- AOA Dx is headquartered in Denver, US.